GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » E10
中文

Kazia Therapeutics (Kazia Therapeutics) E10 : $-1.80 (As of Jun. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kazia Therapeutics's adjusted earnings per share data for the fiscal year that ended in Jun. 2023 was $-0.754. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.80 for the trailing ten years ended in Jun. 2023.

During the past 3 years, the average E10 Growth Rate was 3.90% per year. During the past 5 years, the average E10 Growth Rate was 18.40% per year. During the past 10 years, the average E10 Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Kazia Therapeutics was 34.50% per year. The lowest was 3.40% per year. And the median was 7.30% per year.

As of today (2024-04-25), Kazia Therapeutics's current stock price is $ 0.389. Kazia Therapeutics's E10 for the fiscal year that ended in Jun. 2023 was $-1.80. Kazia Therapeutics's Shiller PE Ratio of today is .


Kazia Therapeutics E10 Historical Data

The historical data trend for Kazia Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics E10 Chart

Kazia Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.16 -2.03 -1.35 -1.73 -1.80

Kazia Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.35 - -1.73 - -1.80

Competitive Comparison of Kazia Therapeutics's E10

For the Biotechnology subindustry, Kazia Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kazia Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Shiller PE Ratio falls into.



Kazia Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kazia Therapeutics's adjusted earnings per share data for the fiscal year that ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.754/124.1700*124.1700
=-0.754

Current CPI (Jun. 2023) = 124.1700.

Kazia Therapeutics Annual Data

per_share_eps CPI Adj_EPS
201406 -4.457 98.352 -5.627
201506 -2.307 99.838 -2.869
201606 -2.087 100.859 -2.569
201706 -0.172 102.809 -0.208
201806 -0.936 104.945 -1.107
201906 -1.240 106.617 -1.444
202006 -1.178 106.246 -1.377
202106 -0.547 110.332 -0.616
202206 -1.327 117.112 -1.407
202306 -0.754 124.170 -0.754

Add all the adjusted EPS together and divide 10 will get our e10.


Kazia Therapeutics  (NAS:KZIA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Kazia Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics (Kazia Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Executives
Josiah T Austin director, 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204